Targeting the Transforming Growth Factor-beta Signaling Pathway in the Treatment of Gynecologic Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The transforming growth factor-beta (TGF-β) signaling pathway is frequently dysregulated in gynecologic cancers.
• Aberrant TGF-β signaling contributes to the development and progression of various malignancies.
• This pathway is recognized as a potential therapeutic target and prognostic biomarker in cervical cancer.

Purpose of the Study:

• To provide an overview of the biological role of TGF-β in gynecologic cancers.
• To review the clinical impact of TGF-β inhibitors in gynecologic cancer treatment.
• To summarize findings from Phase I to Phase III clinical trials of TGF-β inhibitors.

Main Methods:

• Literature review of preclinical and clinical studies.
• Focus on Phase I to Phase III clinical trials of TGF-β inhibitors.
• Analysis of TGF-β inhibitors as single agents or in combination therapy.

Main Results:

• Several TGF-β inhibitors, including galunisertib, dalantercept, and vigil, are under investigation.
• These inhibitors show potential as anticancer agents in ongoing clinical trials.
• Data suggest a potential therapeutic impact of targeting the TGF-β pathway in diverse cancer types.

Conclusions:

• Inhibition of TGF-β signaling is a promising strategy for gynecologic cancer treatment.
• Further research is needed to fully establish the therapeutic value of TGF-β inhibitors.
• Identifying patient populations most likely to benefit from TGF-β targeted therapy is crucial.